Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

China has announced a US$3.49 million (R60 million) partnership with South Africa to expand HIV prevention services among adolescents and young people, as ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion ...

Over the past decade, Kenya has been a global beacon, celebrated for achieving near-universal access to life-saving HIV treatment ...

On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...